Vertex Pharmaceuticals (VRTX) Akcie Kurz
Vertex Pharmaceuticals Kurz
Za posledních 19 let vzrostly tržby Vertex Pharmaceuticals o 23,6 % ročně a dosáhly 12,07 Mld. USD. Zisk na akcii rostl o 40,3 % ročně za posledních 14 let. U Vertex Pharmaceuticals je čistá marže 32,7 % nahoru oproti 30,9 % před několika lety. Konsenzuální 12měsíční cílová cena pro Vertex Pharmaceuticals je 608,00 USD, asi nad cenu o 18,1 %. Z 39 analytiků jich 32 doporučuje nákup — celkový konsenzus je Koupit.
Cena akcie Vertex Pharmaceuticals
Tato data přes Eulerpool API
100 000 požadavků/měs. zdarma · bez karty
Obchodní model Vertex Pharmaceuticals a analýza akcií
Nejčastější otázky týkající se akcie Vertex Pharmaceuticals
The business model of Vertex Pharmaceuticals Inc is focused on researching, developing, and commercializing innovative therapies for serious diseases. Vertex specializes in discovering and developing small molecule drugs that target specific genetic diseases, including cystic fibrosis (CF) and other serious lung and liver diseases. The company's approach involves identifying the underlying cause of these diseases at a molecular level and developing targeted therapies that address the genetic mutations responsible. By leveraging its expertise in genomics and precision medicine, Vertex aims to provide effective treatment options for patients with limited or no existing therapeutic options.
Vertex Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
The main competitors of Vertex Pharmaceuticals Inc in the market include companies like Amgen, Gilead Sciences, and Bristol-Myers Squibb.
Vertex Pharmaceuticals Inc. is a renowned biotechnology company based in Boston, Massachusetts. Founded in 1989, Vertex has emerged as a global leader in developing innovative therapies for serious medical conditions. The company focuses on discovering transformative medicines for diseases including cystic fibrosis, pain, and other debilitating illnesses. Vertex has an esteemed track record of successful breakthroughs, with several FDA-approved drugs in its portfolio. With a strong commitment to research and development, Vertex Pharmaceuticals Inc. continues to pioneer advancements in the field of biotechnology, striving to improve the lives of countless patients worldwide.
Vertex Pharmaceuticals Inc. has achieved several significant milestones throughout its history. One of the most notable achievements is the development of breakthrough treatments for cystic fibrosis (CF). The company successfully introduced the first-ever CF medicine targeting the underlying cause of the disease, known as Kalydeco. Vertex Pharmaceuticals Inc. also made remarkable progress with other CF treatments like Orkambi, Symdeko, and Trikafta, significantly improving the lives of CF patients worldwide. Additionally, the company has expanded its pipeline with innovative therapies, focusing on various diseases including cancer, pain, and genetic disorders. These remarkable milestones highlight Vertex Pharmaceuticals Inc.'s commitment to revolutionize medical treatments and improve patient outcomes.
Vertex Pharmaceuticals Inc is primarily present in several countries and regions. The company has a strong presence in the United States where it is headquartered, with its main facilities and operations located there. Additionally, Vertex Pharmaceuticals Inc has expanded its presence internationally. The company has a significant presence in Europe, including countries such as Germany, France, Italy, and the United Kingdom. Furthermore, Vertex Pharmaceuticals Inc has established operations in Canada and several other countries. With its global reach, Vertex Pharmaceuticals Inc aims to provide innovative pharmaceutical solutions to patients worldwide.
Vertex Pharmaceuticals Inc represents values such as innovation, scientific excellence, and patient-focused approach. The company is committed to discovering transformative medicines to benefit people with serious diseases, with a particular focus on diseases such as cystic fibrosis. Vertex Pharmaceuticals Inc prioritizes research and development, leveraging cutting-edge technologies and expertise to advance their pipeline. With a culture of collaboration and a strong sense of purpose, Vertex Pharmaceuticals Inc aims to make a meaningful impact on patients' lives. By combining scientific expertise and a patient-centric approach, the company is dedicated to improving the quality of life and outcomes for those in need.
Analytici aktuálně stanovují průměrnou cílovou cenu 579,29 USD pro akcii Vertex Pharmaceuticals (medián: 608,00 USD), tedy +11,3 % vůči poslední ceně. Konsensus vychází z 39 hodnocení analytiků.
39 analytiků aktuálně hodnotí akcii Vertex Pharmaceuticals: 32 doporučuje koupit, 6 držet a 1 prodat. Pro rok 2026 analytici očekávají u Vertex Pharmaceuticals tržby 13,26 Mld. USD a zisk na akcii 17,99 USD.
Při aktuálním kurzu se akcie Vertex Pharmaceuticals obchoduje za 469,05 EUR (515,02 USD).
Akcie Vertex Pharmaceuticals (VRTX) je kótována na 11 burzách, mimo jiné: NASDAQ (VRTX), London (0QZU.L), SIX (Zürich) (VRTX.SW), XETRA (VX1.DE), Frankfurt (VX1.F), München (VX1.MU), Düsseldorf (VX1.DU), Hamburg (VX1.HM).
Vertex Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative drugs for the treatment of serious and life-threatening diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts, USA.
Tržby očekávané za Vertex Pharmaceuticals činí 13,26 Mld. USD. Tato hodnota je založena na aktuálních finančních údajích a odráží výkonnost společnosti.
Zisk očekávané za Vertex Pharmaceuticals činí 4,61 Mld. USD. Čistý zisk odráží ziskovost společnosti po odečtení všech nákladů.
Poměr ceny k zisku (P/E) Vertex Pharmaceuticals je aktuálně 28,63. Poměr P/E porovnává aktuální cenu akcie se ziskem na akcii a pomáhá investorům posoudit ocenění akcie Vertex Pharmaceuticals.
Poměr ceny k tržbám (P/S) Vertex Pharmaceuticals je aktuálně 9,95. Poměr P/S porovnává tržní kapitalizaci s ročními tržbami a slouží jako metrika ocenění akcie Vertex Pharmaceuticals.
Score kvality pro Vertex Pharmaceuticals je 6/10.
ISIN Vertex Pharmaceuticals je US92532F1003. ISIN (International Securities Identification Number) je celosvětově jedinečný identifikátor cenných papírů.
WKN Vertex Pharmaceuticals je 882807. WKN (Wertpapierkennnummer) je šestimístný německý identifikační kód cenného papíru.
Ticker Vertex Pharmaceuticals je VRTX. Symbol tickeru se používá k obchodování akcií Vertex Pharmaceuticals na burze.
Vertex Pharmaceuticals akcie
Vertex Pharmaceuticals Peer Group
Vertex Pharmaceuticals Ticker
Vertex Pharmaceuticals FIGI
Všechny fundamentální údaje o Vertex Pharmaceuticals v podrobné analýze
Naše analýzy akcií společnosti Vertex Pharmaceuticals zahrnují důležité finanční ukazatele jako obrat, zisk, P/E poměr, P/S poměr, EBIT, stejně jako informace o dividendách. Dále zkoumáme aspekty jako akcie, tržní kapitalizaci, dluhy, vlastní kapitál a závazky společnosti Vertex Pharmaceuticals. Pokud hledáte podrobnější informace o těchto tématech, nabízíme vám na našich podstránkách rozsáhlé analýzy:





